Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: Subgroup analyses in the Cholesterol And Recurrent Events (CARE) trial

Circulation

Volumn 98, Issue 23, 1998, Pages 2513-2519

  Goldberg, Ronald B ^a   Mellies, Margot J ^c   Sacks, Frank M ^g,h   Moyé, Lemuel A ^b   Howard, Barbara V ^d   Howard, William James ^e   Davis, Barry R ^b   Cole, Thomas G ^f   Pfeffer, Marc A ^g   Braunwald, Eugene ^g  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

^d Medlantic Research Institute   (United States)

^e WASHINGTON HOSPITAL CENTER   (United States)

^f WASHINGTON UNIVERSITY   (United States)

^g BRIGHAM AND WOMEN S HOSPITAL   (United States)

^h HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Coronary disease; Diabetes mellitus; Glucose; Lipoproteins

Indexed keywords

PRAVASTATIN;

ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY RISK; DIABETES MELLITUS; DRUG EFFECT; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0032497945     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.98.23.2513     Document Type: Article

References (24)

1. Kannel WB, McGee DL. Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham Study. Diabetes Care. 1979;2:120-126.
2. Wingard DL, Barrett-Connor E. Heart disease and diabetes. In: Harris MI, ed. Diabetes in America. 2nd ed. Bethesda, Md: National Institutes of Health, National Institutes of Diabetes and Digestive and Kidney Disease; 1995;429-448. NIH publication 95-1468.
3. Leitersdorf E, Gottchrer N, Fainaru M, Friedlander Y, Friedman G, Tzivoni D, Stein Y. Analysis of risk factors in 532 survivors of first myocardial infarction hospitalized in Jerusalem. Atherosclerosis. 1976; 59:75-93.
4. Pyörälä K, Laakso M, Uusitupa M. Diabetes and atherosclerosis: an epidemiologic view. Diabetes Metab Rev. 1987;3:463-524.
5. Wilson PW, Kannel WB, Anderson KM. Lipids, glucose tolerance and vascular disease: the Framingham study. Monogr Atheroscler. 1985;13:1-11.
6. Klein R. Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes Care. 1995;18:258-268.
7. West KM, Ahuja MMS, Bennett PH, Czyzyk A, De Acosta OM, Fuller JH, Grab B, Grabauskas V, Jarrett, RJ, Kosaka K, Keen H, Krolewski AS, Miki E, Schliack V, Teuscher A, Watkins, PJ, Stober JA. The role of circulating glucose and triglyceride concentrations and their interactions with other "risk factors" as determinants of arterial disease in nine diabetic population samples from the WHO multinational study. Diabetes Care. 1983;6:361-369.
8. Ohlson L-O, Bjuro T., Larsson B, Eriksson H, Svardsudd K, Welin L, Wilhelmsen L. A cross-sectional analysis of glucose tolerance and cardiovascular disease in 67-year-old men. Diabetes Med. 1989;6:112-120.
9. Lowe L. P., Liu K, Greenland O, Metzger BE, Dyer AR, Stamler J. Diabetes, asymptomatic hyperglycemia, and 22-year mortality in black and white men. Diabetes Care. 1997;20:163-169.
10. Pyörälä K, Pedersen TR, Kjeksus J, Faergeman O, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care. 1997;20:614-620.
11. Sacks FM, Pfeffer MA, Moyé LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JMO, Wun C, Davis BR, Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Events Trial Investigators. N Engl J Med. 1996;335:1001-1009.
12. Sacks FM, Pfeffer MA, Moyé L, Brown LE, Hamm P, Cole TG. Hawkins CM, Braunwald E. Rationale and design of a secondary prevention trial of lowering normal plasma cholesterol levels after acute myocardial infarction: the Cholesterol and Recurrent Events Trial (CARE). Am J Cardiol. 1991;68:1436-1446.
13. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol (Adult Treatment Panel II). JAMA. 1993;209:3015-3023.
14. Friedewald WT, Levy RI, Frederickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
15. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 1997;20:1183-1197.
16. Kalbfleisch ID, Prentice RI. The Statistical Analysis of Failure Time Data. New York, NY: John Wiley & Sons Inc; 1980.
17. Cox DR. Regression models and life tables. J R Stat Soc (B). 1972;34: 187-220.
18. Sprafka IM, Burke GL, Folsom AR, McGovern, PG, Hahn LP. Trends in prevalence of diabetes mellitus in patients with myocardial infarction and effect of diabetes on survival: the Minnesota Heart Survey. Diabetes Care. 1991;14:537-543.
19. Plan and operation of the Second National Health and Nutrition Examination Survey. Vital and Health Statistics. Washington, DC: National Center for Health Statistics; 1981. Series 1, No. 15.
20. Cowie CC, Harris MI. Physical and metabolic characteristics of persons with diabetes. In: Harris MI, ed. Diabetes in America. 2nd ed. Bethesda, Md: National Institutes of Health, National Institutes of Diabetes and Digestive and Kidney Disease; 1995:117-164. NIH publication 95-1468.
21. Harris MI. Epidemiological correlates of NIDDM in Hispanics, whites and blacks in the US population. Diabetes Care. 1991;14(suppl 3):639-648.
22. Barrett-Connor EL, Cohn BA, Wingard DL, Edelstein SL. Why is diabetes mellitus a stronger risk factor for fatal ischemic heart disease in women than men? JAMA. 1991;265:627-631.
23. Harris MI, Hadden WC, Knowler WC, Bennet PH. Prevalence of diabetes and impaired glucose tolerance and plasma glucose levels in US population aged 20-74 years. Diabetes. 1987;36:523-534.
24. Fuller JH, Shipley MJ, Rose G, Jarrett RJ, Keen H. Coronary heart disease and impaired glucose tolerance. Lancet. 1980;1:1373-1376.